Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
2024年10月3日 - 10:00PM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, and Ultima Genomics, Inc., a developer of a
revolutionary new ultra-high throughput next-generation sequencing
(NGS) platform, today announced a joint effort to explore Ultima’s
UG 100™ sequencing platform and its ppmSeq™ technology to
advance Myriad’s ability to offer groundbreaking clinical tests.
Myriad has purchased a new UG 100 that will soon join other leading
sequencing platforms in its new Lab of the Future facility in South
San Francisco.
The low-cost and low-error sequencing achievable on the UG 100
may benefit several of Myriad’s emerging products that require
large amounts of high-fidelity sequencing data. The Myriad Precise
Molecular Residual Disease (MRD) test performs whole-genome
sequencing on two samples from cancer patients—one from a tumor and
one from normal tissue—to comprehensively identify tumor-specific
variants for subsequent tracking in a personalized panel. With
Ultima’s support, Myriad will explore the potential for the Precise
MRD test to improve in both performance and cost with ppmSeq on the
UG 100. In the reproductive-health space, Myriad is expected to
launch its FirstGene Multiple Prenatal Screen, which will run the
content of multiple prenatal screens via a single sequencing
workflow. FirstGene also requires deep and accurate sequencing that
the UG 100 platform may be well suited to affordably provide.
"We are delighted to get a UG 100 into our laboratory and
work with Ultima Genomics to investigate how it can help us advance
patient care,” said Sam Raha, Chief Operating Officer, Myriad
Genetics. “A key part of our mission is to make relevant
cutting-edge genetic testing broadly accessible. We regularly
evaluate new platforms that have the possibility of supporting our
mission. As part of that process, we have identified the UG
100 as a potentially transformative platform that may provide
an industrial sequencing center like ours the opportunity to lower
costs, improve quality, and deepen insights simultaneously. It
could influence how we offer and innovate upon some of our
promising tests like Precise MRD and FirstGene, which are expected
to enter the market in the near future, and it may also support us
in exploring new areas with future products that may have been
challenging to pursue otherwise.”
“We are pleased to be working with Myriad, a precision medicine
leader, in the fast-evolving field of MRD, as well as exploring
opportunities to deploy whole genome sequencing in other
application areas,” said Gilad Almogy, CEO of Ultima Genomics.
“Ultima’s unique sequencing architecture was designed to
specifically meet the needs of large-scale applications. For
oncology applications, our ppmSeq technology offers accuracy at
extremely low limits of detection and we believe this will be
transformational for applications requiring earlier detection such
as MRD. Additionally, our low-cost sequencing offers an opportunity
to affordably transition testing methods towards whole genome
approaches where previously it was not possible due to the high
costs of sequencing.”
About Myriad Genetics Myriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com. About Ultima GenomicsUltima
Genomics is unleashing the power of genomics at scale. The
Company's mission is to continuously drive the scale of genomic
information to enable unprecedented advances in biology and
improvements in human health. With humanity on the cusp of a
biological revolution, there is a virtually endless need for more
genomic information to address biology's complexity and dynamic
change—and a further need to challenge conventional next-generation
sequencing technologies. Ultima's revolutionary new sequencing
architecture drives down the costs of sequencing to help overcome
the tradeoffs that scientists and clinicians are forced to make
between the breadth, depth and frequency with which they use
genomic information. The new sequencing architecture was designed
to scale far beyond conventional sequencing technologies, lower the
cost of genomic information and catalyze the next phase of genomics
in the 21st century. To learn more, visit
www.ultimagenomics.com/
Myriad Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the company’s purchase and expected
installation of a UG 100 device in the company’s new Lab of the
Future facility in South San Francisco and the potential benefits
of the UG 100 device, that the company, with Ultima’s support, will
explore the potential for the Precise MRD test to improve both
performance and cost with ppmSeq and the UG 100, and that the
company expects to launch Precise MRD and FirstGene in the near
future. These “forward-looking statements” are management’s
expectations of future events as of the date hereof and are subject
to known and unknown risks and uncertainties that could cause
actual results, conditions, and events to differ materially and
adversely from those anticipated. Such factors include those risks
described in the company’s filings with the U.S. Securities and
Exchange Commission, including the company’s Annual Report on Form
10-K filed on February 28, 2024, as well as any updates to those
risk factors filed from time to time in the company’s Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not
under any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Myriad Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Myriad Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
Ultima Media ContactVikki
Herrera408-206-7009vikki@oakstreetcommunications.com
Myriad Genetics (NASDAQ:MYGN)
過去 株価チャート
から 9 2024 まで 10 2024
Myriad Genetics (NASDAQ:MYGN)
過去 株価チャート
から 10 2023 まで 10 2024